ES2094132T3 - Uso de derivados de xantina contra la ulcera peptica. - Google Patents

Uso de derivados de xantina contra la ulcera peptica.

Info

Publication number
ES2094132T3
ES2094132T3 ES90115456T ES90115456T ES2094132T3 ES 2094132 T3 ES2094132 T3 ES 2094132T3 ES 90115456 T ES90115456 T ES 90115456T ES 90115456 T ES90115456 T ES 90115456T ES 2094132 T3 ES2094132 T3 ES 2094132T3
Authority
ES
Spain
Prior art keywords
peptica
ulcera
xantina
derivatives against
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90115456T
Other languages
English (en)
Inventor
Toshizo Tanaka
Shoryo Hayashi
Yuko Morioka
Ulrich Dr Gebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of ES2094132T3 publication Critical patent/ES2094132T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

AGENTES TERAPEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES DE ULCERA PEPTICA QUE CONTIENEN COMO INGREDIENTE ACTIVO AL MENOS UN COMPUESTO DE FORMULA GENERAL I, EN DONDE UNO DE LOS R1 Y R3 ES (EN DONDE M ES 1-5, R4 REPRESENTA UN GRUPO ALQUILO C1-C4); EL RESTANTE DE R1 O R3 ES HIDROGENO, ALQUENILO C3-C6 O ALQUILO C1-C8, EL CUAL PUEDE ESTAR SUSTITUIDO CON HASTA 2 GRUPOS HIDROXILO O UN GRUPO ALCOXILO C1-C4; Y R2 ES ALQUILO C1-C4.
ES90115456T 1989-08-16 1990-08-11 Uso de derivados de xantina contra la ulcera peptica. Expired - Lifetime ES2094132T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21018789 1989-08-16

Publications (1)

Publication Number Publication Date
ES2094132T3 true ES2094132T3 (es) 1997-01-16

Family

ID=16585226

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90115456T Expired - Lifetime ES2094132T3 (es) 1989-08-16 1990-08-11 Uso de derivados de xantina contra la ulcera peptica.

Country Status (18)

Country Link
US (1) US5109003A (es)
EP (1) EP0413278B1 (es)
JP (1) JP2977242B2 (es)
KR (1) KR910004620A (es)
AT (1) ATE144900T1 (es)
AU (1) AU624987B2 (es)
CA (1) CA2023310A1 (es)
DD (1) DD298051A5 (es)
DE (1) DE69029069T2 (es)
DK (1) DK0413278T3 (es)
ES (1) ES2094132T3 (es)
GR (1) GR3021569T3 (es)
HU (1) HU207518B (es)
IE (1) IE902954A1 (es)
IL (1) IL95377A (es)
NZ (1) NZ234896A (es)
PT (1) PT95007A (es)
ZA (1) ZA906446B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5354756A (en) * 1993-01-12 1994-10-11 Cell Therapeutics, Inc. Olefin-substituted long chain xanthine compounds
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤

Also Published As

Publication number Publication date
JP2977242B2 (ja) 1999-11-15
HUT54688A (en) 1991-03-28
PT95007A (pt) 1991-04-18
NZ234896A (en) 1993-10-26
CA2023310A1 (en) 1991-02-17
IL95377A (en) 1994-08-26
GR3021569T3 (en) 1997-02-28
ATE144900T1 (de) 1996-11-15
KR910004620A (ko) 1991-03-29
AU624987B2 (en) 1992-06-25
EP0413278B1 (en) 1996-11-06
JPH03163019A (ja) 1991-07-15
US5109003A (en) 1992-04-28
ZA906446B (en) 1991-05-29
AU6101890A (en) 1991-02-21
EP0413278A3 (en) 1992-05-06
DD298051A5 (de) 1992-02-06
HU905000D0 (en) 1991-01-28
IE902954A1 (en) 1991-02-27
DE69029069D1 (de) 1996-12-12
IL95377A0 (en) 1991-06-30
HU207518B (en) 1993-04-28
DE69029069T2 (de) 1997-04-10
DK0413278T3 (da) 1997-04-07
EP0413278A2 (en) 1991-02-20

Similar Documents

Publication Publication Date Title
ATE62415T1 (de) Substituierte bicyclische verbindungen.
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
ES2087097T3 (es) Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
ES2002254A4 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
DK106586D0 (da) Cyklopenta(d)pyrimidinderivater samt deres fremstilling og anvendelse
FI860369A0 (fi) Imidazolderivat, deras framstaellning och anvaendning samt dessa derivat innehaollande farmaceutiska kompositioner.
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
FI844225A0 (fi) Griseolinsyraderivat och deras anvaendning.
SE8100403L (sv) Cyklohexen-derivat
ES2094132T3 (es) Uso de derivados de xantina contra la ulcera peptica.
FI831431A0 (fi) Bensotiazolinfoereningar
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
ES2039719T3 (es) Procedimiento para preparar un agente terapeutico para el tratamiento de la enfermedad de ulcera peptica.
DE69023939D1 (de) Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.
ES2037758T3 (es) Un metodo de uso de un derivado quinolincarboxilico y su procedimiento de preparacion.
SE8302345L (sv) Pleuromutilinderivat, forfaranden for deras framstellning och deras anvendning som lekemedel
DK601583D0 (da) Carbamyloxybenzhydrolderivater
DK520787A (da) Terapeutisk middel indeholdende propentofyllin eller derivater deraf til brug ved behandling af peptisk ulcus
MX9203068A (es) Compuestos activirales oralmente activos.
ES2043605T3 (es) Procedimiento de preparacion de nuevos derivados del 4-morfolinil-1h-indol.
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.
DK315785D0 (da) Phenylethylaminopropiophenon-derivater, deres fremstilling og anvendelse som laegemidler
NO932002L (no) Nye tiosemikarbazonsyreestere
AR014135A1 (es) Profarmacos de lobucavir y metodos de uso
KR890002222A (ko) 치매 치료제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 413278

Country of ref document: ES